MapLight Therapeutics (MPLT) Net Cash Flow (2024 - 2025)
MapLight Therapeutics (MPLT) posted Net Cash Flow of -$17.4 million for Q4 2025, down 259.63% sequentially from $10.9 million in Q4 2024, and down 259.63% YoY from $10.9 million in Q4 2024.
MapLight Therapeutics (MPLT) Net Cash Flow (2024 - 2025) Analysis & Trends
MapLight Therapeutics has reported Net Cash Flow for 2 years, with the latest figure at -$17.4 million in Q4 2025.
- Quarterly Net Cash Flow fell 259.63% year-over-year to -$17.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$6.5 million (changed N/A YoY) and the FY2025 annual result came in at $8.5 million, up 120.4% from the prior year.
- Net Cash Flow slipped to -$17.4 million in Q4 2025 per MPLT's latest filing, from $10.9 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $10.9 million in Q4 2024 and troughed at -$17.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | MapLight Therapeutics | 533.88 Mn | 533.88 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -17.42 Mn |
| Dec 31, 2025 | -17.42 Mn |
| Dec 31, 2024 | 10.91 Mn |
| Dec 31, 2024 | 10.91 Mn |